Overview
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.
Eligibility
Inclusion Criteria:
- Male or female aged 6 months to 11 years old at baseline.
- Patients with severe Atopic dermatitis (AD) according to the investigator's assessment.
- Patients initiating dupilumab (in those patients initiated retrospectively 2 months before the start of the study, the baseline information must be correctly filled out in the medical records).
- Signed informed consent by the parent/legally acceptable representative and assent by the patient appropriate to the patient's age.
Exclusion Criteria:
- Patients who are participating in an interventional clinical trial that modifies patient care.